- Home
- ELVN vs KALU Comparison
ELVN vs KALU Comparison
Compare ELVN & KALU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- KALU
- Stock Information
- Founded
- ELVN 2016
- KALU 1946
- Country
- ELVN United States
- KALU United States
- Employees
- ELVN N/A
- KALU N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- KALU Metal Fabrications
- Sector
- ELVN Health Care
- KALU Industrials
- Exchange
- ELVN Nasdaq
- KALU Nasdaq
- Market Cap
- ELVN 1.0B
- KALU 1.1B
- IPO Year
- ELVN 2020
- KALU 1991
- Fundamental
- Price
- ELVN $22.54
- KALU $70.20
- Analyst Decision
- ELVN Strong Buy
- KALU Buy
- Analyst Count
- ELVN 5
- KALU 2
- Target Price
- ELVN $37.80
- KALU $90.00
- AVG Volume (30 Days)
- ELVN 269.1K
- KALU 84.8K
- Earning Date
- ELVN 03-13-2025
- KALU 02-19-2025
- Dividend Yield
- ELVN N/A
- KALU 4.40%
- EPS Growth
- ELVN N/A
- KALU 252.66
- EPS
- ELVN N/A
- KALU 2.90
- Revenue
- ELVN N/A
- KALU $2,980,300,000.00
- Revenue This Year
- ELVN N/A
- KALU N/A
- Revenue Next Year
- ELVN N/A
- KALU $6.84
- P/E Ratio
- ELVN N/A
- KALU $24.16
- Revenue Growth
- ELVN N/A
- KALU N/A
- 52 Week Low
- ELVN $10.90
- KALU $60.71
- 52 Week High
- ELVN $30.03
- KALU $102.42
- Technical
- Relative Strength Index (RSI)
- ELVN 47.03
- KALU 42.74
- Support Level
- ELVN $20.40
- KALU $68.27
- Resistance Level
- ELVN $22.42
- KALU $70.58
- Average True Range (ATR)
- ELVN 1.25
- KALU 2.03
- MACD
- ELVN 0.06
- KALU -0.04
- Stochastic Oscillator
- ELVN 59.59
- KALU 24.97
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from United States.